Approval · Notice of Compliance 35152 · 2025
IMFINZI: Notice of Compliance 35152
Issued April 10, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35152
- Date
- April 10, 2025
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: Metastatic Non-Small Cell Lung Cancer Imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| IMFINZI | Not yet assigned | — |
Medicinal ingredients
- DURVALUMAB 50 MG per ML